How does IRD's PS Ratio compare to its peers?

IRD is good value based on its Price-To-Sales Ratio (4.1x) compared to the peer average (10.3x).

How does IRD's PS Ratio compare vs other companies in the US Pharmaceuticals Industry?

IRD is expensive based on its Price-To-Sales Ratio (4.1x) compared to the US Pharmaceuticals industry average (2.9x).

What is IRD's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

IRD is expensive based on its Price-To-Sales Ratio (4.1x) compared to the estimated Fair Price-To-Sales Ratio (2.3x).

What is the Fair Price of IRD when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Insufficient data to calculate IRD's fair value for valuation analysis.

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Opus Genetics (Nasdaq:IRD) - Stock Price, News & Analysis

IRD Stock Overview

A clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. More details

IRD fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	2/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Rewards

Revenue is forecast to grow 62.01% per year

Risk Analysis

Has less than 1 year of cash runway

Volatile share price over the past 3 months compared to the US market

Shareholders have been diluted in the past year

Does not have a meaningful market cap ($35M)

+ 1 more risk

Opus Genetics, Inc. Competitors

IGC Pharma

NYSEAM:IGC

US$29.0m

Pulmatrix

NasdaqCM:PULM

US$22.1m

SCYNEXIS

NasdaqGM:SCYX

US$47.1m

Lyra Therapeutics

NasdaqGM:LYRA

US$12.4m

Price History & Performance

Summary of all time highs, changes and price drops for Opus Genetics
Historical stock prices
Current Share Price	US$1.09
52 Week High	US$3.40
52 Week Low	US$0.85
Beta	0.32
11 Month Change	-6.84%
3 Month Change	-10.66%
1 Year Change	-59.63%
33 Year Change	-72.12%
5 Year Change	n/a
Change since IPO	-81.83%

Recent updates

Analyst Forecasts For Ocuphire Pharma, Inc. (NASDAQ:OCUP) Are Surging Higher

Aug 19

Investors Still Aren't Entirely Convinced By Ocuphire Pharma, Inc.'s (NASDAQ:OCUP) Revenues Despite 30% Price Jump

Jul 24

Companies Like Ocuphire Pharma (NASDAQ:OCUP) Are In A Position To Invest In Growth

Jul 12

Slammed 26% Ocuphire Pharma, Inc. (NASDAQ:OCUP) Screens Well Here But There Might Be A Catch

May 02

Ocuphire Pharma, Inc. (NASDAQ:OCUP) Shares May Have Slumped 26% But Getting In Cheap Is Still Unlikely

Mar 15

Analysts Just Shaved Their Ocuphire Pharma, Inc. (NASDAQ:OCUP) Forecasts Dramatically

May 20

Ocuphire completes patient enrollment for phase 2 trial of diabetic retinopathy treatment

Sep 08

Ocuphire Pharma GAAP EPS of -$0.25 beats by $0.08

Aug 12

Ocuphire extends IP rights for lead candidate with new U.S. patent

Aug 03

Ocuphire gets new U.S. patent for its oral drug candidate APX3330 for use in diabetics

Jun 29

We're Keeping An Eye On Ocuphire Pharma's (NASDAQ:OCUP) Cash Burn Rate

Jun 24

Is Ocuphire Pharma (NASDAQ:OCUP) In A Good Position To Invest In Growth?

Mar 22

Here's Why We're Not Too Worried About Ocuphire Pharma's (NASDAQ:OCUP) Cash Burn Situation

Oct 08

Ocuphire Pharma: An Undervalued Ophthalmic Play

Aug 05

Ocuphire Pharma inks licensing deal for RX-3117 with Processa Pharma

Jun 17

Ocuphire Pharma (NASDAQ:OCUP) Is In A Good Position To Deliver On Growth Plans

Jun 11

Shareholder Returns

	IRD	US Pharmaceuticals	US Market
7D	23.4%	2.8%	2.2%
1Y	-59.6%	11.8%	32.6%

Return vs Industry: IRD underperformed the US Pharmaceuticals industry which returned 11.8% over the past year.

Return vs Market: IRD underperformed the US Market which returned 32.6% over the past year.

Price Volatility

Is IRD's price volatile compared to industry and market?
IRD volatility
IRD Average Weekly Movement	10.4%
Pharmaceuticals Industry Average Movement	9.5%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.8%
10% least volatile stocks in US Market	3.1%

Stable Share Price: IRD's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: IRD's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

Founded	Employees	CEO	Website
2018	14	George Magrath	opusgtx.com

Opus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances. Its lead retinal product candidate is APX3330, a small-molecule inhibitor of reduction oxidation effector factor-1 protein that has completed Phase II clinical trial for the treatment of diabetic retinopathy.

Opus Genetics, Inc. Fundamentals Summary

How do Opus Genetics's earnings and revenue compare to its market cap?
IRD fundamental statistics
Market cap	US$34.73m
Earnings (TTM)	-US$27.19m
Revenue (TTM)	US$8.38m

4.1x

P/S Ratio

-1.3x

P/E Ratio

Is IRD overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
IRD income statement (TTM)
Revenue	US$8.38m
Cost of Revenue	US$23.77m
Gross Profit	-US$15.39m
Other Expenses	US$11.80m
Earnings	-US$27.19m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.86
Gross Margin	-183.63%
Net Profit Margin	-324.45%
Debt/Equity Ratio	0%

How did IRD perform over the long term?

See historical performance and comparison

IRD Stock Overview

Rewards

Risk Analysis

Opus Genetics, Inc. Competitors

NYSEAM:IGC

US$29.0m

NasdaqCM:PULM

US$22.1m

NasdaqGM:SCYX

US$47.1m

NasdaqGM:LYRA

US$12.4m

Price History & Performance

Recent News & Updates

CEO & Director recently bought US$101k worth of stock

Consensus revenue estimates increase by 40%, EPS downgraded

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased by 21% to US$13.67

Ocuphire Pharma, Inc. (NasdaqCM:OCUP) acquired Opus Genetics, Inc. for $25.8 million.

Ocuphire Pharma Announces Publication of Full Phase 3 Results of Phentolamine Ophthalmic Solution 0.75% for Pharmacologically-Induced Mydriasis in Ophthalmology

Recent updates

CEO & Director recently bought US$101k worth of stock

Consensus revenue estimates increase by 40%, EPS downgraded

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased by 21% to US$13.67

Ocuphire Pharma, Inc. (NasdaqCM:OCUP) acquired Opus Genetics, Inc. for $25.8 million.

Ocuphire Pharma Announces Publication of Full Phase 3 Results of Phentolamine Ophthalmic Solution 0.75% for Pharmacologically-Induced Mydriasis in Ophthalmology

Analyst Forecasts For Ocuphire Pharma, Inc. (NASDAQ:OCUP) Are Surging Higher

Consensus revenue estimates increase by 62%

Second quarter 2024 earnings: EPS in line with expectations, revenues disappoint

Price target decreased by 12% to US$17.25

Investors Still Aren't Entirely Convinced By Ocuphire Pharma, Inc.'s (NASDAQ:OCUP) Revenues Despite 30% Price Jump

Companies Like Ocuphire Pharma (NASDAQ:OCUP) Are In A Position To Invest In Growth

Ocuphire Pharma Announces Presentations on the Development of APX3330 for Diabetic Retinopathy At Retina Meetings in June

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Slammed 26% Ocuphire Pharma, Inc. (NASDAQ:OCUP) Screens Well Here But There Might Be A Catch

Ocuphire Pharma, Inc., Annual General Meeting, Jun 11, 2024

Ocuphire Pharma, Inc. Announces the Enrollment of the First Subject in the LYNX-2 Phase 3 registration study

Ocuphire Pharma, Inc. (NASDAQ:OCUP) Shares May Have Slumped 26% But Getting In Cheap Is Still Unlikely

Full year 2023 earnings: EPS and revenues miss analyst expectations

Ocuphire Pharma, Inc. Announces Appointments of Nirav Jhaveri, C.F.A., M.B.A. as Chief Financial Officer

Ocuphire Pharma, Inc. Announces Presentation of Clinical Data from Its ZETA-1 Trial on A Person-Level Scale Evaluating APX3330 in Diabetic Retinopathy

Ocuphire Pharma, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Investor sentiment improves as stock rises 17%

Ocuphire Pharma, Inc. Promotes Ronil Patel to Chief Business Officer, Effective as of December 1, 2023

Insufficient new directors

Ocuphire Pharma Announces Appointment of Joseph Schachle, M.B.A., as Chief Operating Officer

Ocuphire Pharma Announces Appointment of Joseph Schachle, M.B.A., as Chief Operating Officer

Consensus revenue estimates increase by 24%

New minor risk - Shareholder dilution

Ocuphire Pharma, Inc. Announces Chief Executive Officer Changes

Investor sentiment deteriorates as stock falls 16%

Viatris Inc. and Ocuphire Pharma, Inc. Announce Fda Approval of Ryzumvl™? (Phentolamine Ophthalmic Solution) 0.75% Eye Drops for the Treatment of Pharmacologically-Induced Mydriasis Produced by Adrenergic Agonists (E.G., Tropicamide) Agents

New major risk - Revenue and earnings growth

Ocuphire Pharma, Inc. to Present at American Society of Retina Specialists Annual Meeting and OIS Retina Innovation Summit

Ocuphire Pharma, Inc. Presents APX3330 ZETA-1 Clinical Data in Late-Breaker Session at the American Diabetes Association's Annual Conference

Investor sentiment deteriorates as stock falls 19%

Consensus revenue estimates fall by 15%

Analysts Just Shaved Their Ocuphire Pharma, Inc. (NASDAQ:OCUP) Forecasts Dramatically

Price target decreased by 7.8% to US$20.75

Investor sentiment deteriorates as stock falls 18%

Investor sentiment improves as stock rises 31%

Ocuphire Pharma, Inc. Just Beat Revenue Estimates By 42%

Ocuphire Pharma, Inc. Announces FDA Acceptance of New Drug Application and PDUFA Date of September 28, 2023 for Nyxol Eye Drops for Reversal of Mydriasis

Consensus revenue estimates increase by 45%

Ocuphire Pharma, Inc. Announces Topline Results from ZETA-1 Phase 2 Trial of Oral APX3330 in Diabetic Retinopathy and Plans for End-of-Phase 2 Meeting with FDA

We're Keeping An Eye On Ocuphire Pharma's (NASDAQ:OCUP) Cash Burn Rate

Price target decreased by 12% to US$20.40

Ocuphire Pharma Announces First Patient Enrolled in Vega-2 Pivotal Phase 3 Trial of Nyxol® in Presbyopia

Ocuphire Pharma, Inc. Announces Submission of New Drug Application to FDA for Nyxol Eye Drops for Reversal of Mydriasis

High number of new and inexperienced directors

Forecast to breakeven in 2022

Forecast to breakeven in 2024

Ocuphire Pharma, Inc. Announces Peer-Reviewed Publication in BMC Ophthalmology for Nyxol and Strategic Partnership with American Society of Ophthalmic Administrators

We Think Ocuphire Pharma (NASDAQ:OCUP) Needs To Drive Business Growth Carefully

Ocuphire Expands Medical Advisory Board with Seven New Kols and Strengthens Leadership Team

Ocuphire Pharma, Inc. Announces Last Patient Completes Final Visit in ZETA-1 Phase 2b 24-Week Trial of Oral APX3330 in Diabetic Retinopathy

Ocuphire completes patient enrollment for phase 2 trial of diabetic retinopathy treatment

Ocuphire Pharma GAAP EPS of -$0.25 beats by $0.08

Ocuphire extends IP rights for lead candidate with new U.S. patent